FUJIAN WANCHEN BIOTECHNOLOGY GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.89 CNY | -1.52% |
|
+1.64% | -25.71% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Fishing & Farming
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -25.71% | 665M | - | ||
| +17.55% | 1.03B | - | C- | |
| +20.91% | 864M | C | ||
| 0.00% | 780M | - | - | |
| -4.69% | 409M | - | - | |
| +4.44% | 365M | - | - | |
| -10.47% | 331M | - | - | |
| -25.05% | 302M | - | - | |
| -10.14% | 268M | C- | ||
| -10.78% | 251M | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 300972 Stock
- Ratings Fujian Wanchen Biotechnology Group Co., Ltd.